Download PDF

Other users also viewed these articles

Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries J.M. Reyes; M.V. Gutierrez; H. Madariaga; W. Otero; R. Guzman; J. Izquierdo; M. Abello; P. Velez; D. Castillo; D. Ponce de Leon; T. Lukic; L. Amador;
Reumatol Clin. 2023;19:319-27
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;
Reumatol Clin. 2023;19:533-48
JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature Carmen Olga Sánchez González; Juan Carlos Nieto González;
Reumatol Clin. 2022;18:453-8